Center-Authored Papers

Filters: Author is Garzotto, Mark  [Clear All Filters]
2009
Qian DZ, Huang C-Y, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS et al..  2009.  Prostate cancer-associated gene expression alterations determined from needle biopsies.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(9):3135-42. Abstract
2010
Geng H, Rademacher BL, Pittsenbarger J, Huang C-Y, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM et al..  2010.  ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.. Cancer research. 70(8):3239-48. Abstract
Qian DZ, Rademacher BLS, Pittsenbarger J, Huang C-Y, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.  2010.  CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.. The Prostate. 70(4):433-42. Abstract
2014
Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D et al..  2014.  Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA et al..  2014.  Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
2017
Bergstrom CP, Ruffell B, Ho CMT, Higano CS, Ellis WJ, Garzotto M, Beer TM, Graff JN.  2017.  Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.. Anti-cancer drugs. 28(1):120-126. Abstract